Spero Therapeutics' (SPRO) "Hold" Rating Reiterated at TD Cowen

TD Cowen reiterated their hold rating on shares of Spero Therapeutics (NASDAQ:SPRO - Free Report) in a report issued on Monday,Benzinga reports.

Several other analysts have also recently commented on the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Spero Therapeutics in a report on Friday. HC Wainwright reduced their target price on Spero Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a report on Monday, November 4th.

Spero Therapeutics Stock Performance

Shares of Spero Therapeutics stock traded down $0.04 on Monday, hitting $1.14. The stock had a trading volume of 454,452 shares, compared to its average volume of 219,887. The stock has a 50 day moving average of $1.29 and a 200 day moving average of $1.36. Spero Therapeutics has a twelve month low of $1.01 and a twelve month high of $1.89. The firm has a market capitalization of $61.55 million, a P/E ratio of 16.29 and a beta of 0.63.

Hedge Funds Weigh In On Spero Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC raised its position in shares of Spero Therapeutics by 14.2% during the second quarter. Renaissance Technologies LLC now owns 975,952 shares of the company's stock worth $1,269,000 after purchasing an additional 121,492 shares during the period. Acadian Asset Management LLC raised its position in Spero Therapeutics by 40.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company's stock valued at $1,392,000 after buying an additional 309,262 shares during the last quarter. Virtu Financial LLC purchased a new stake in Spero Therapeutics in the 1st quarter valued at $31,000. Murchinson Ltd. raised its position in Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company's stock valued at $1,503,000 after buying an additional 11,210 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Spero Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company's stock valued at $2,844,000 after buying an additional 9,675 shares during the last quarter. 25.60% of the stock is currently owned by institutional investors.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.